Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, and Dr. Robert Lütjens, Head of Discovery – Biology, will be attending 22nd Bio€quity Europe Conference taking place May 16 – 18, 2022, in Milan, Italy. Mr. Dyer has also submitted a pre-recorded video presentation to the conference, in which he provides a corporate update and discusses recent developments at Addex. The presentation will be available for...